BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Life Technologies (LIFE) 400 Base-Pair Sequencing Kit for Ion PGM™ Sequencer Delivers Reads 60 Percent Longer Than Comparable High-Throughput Benchtop Sequencers


12/19/2012 8:55:09 AM

CARLSBAD, Calif., Dec. 19, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) announced today a new 400 base-pair sequencing kit for the Ion PGM Sequencer. The kit produces reads 60 percent longer than comparable high-throughput benchtop sequencers, generating more complete bacterial de novo assemblies with longer contiguous sequences. To see a video about the 400 bp kit and other new products, click here.

"Ion Torrent's long, accurate 400 base pair reads enable excellent bacterial de novo assembly," said Professor Dag Harmsen, Head of Research, Department of Periodontology, University of Muenster, who used the Ion PGM Sequencer to help crack the E. coli outbreak in Germany in 2011. "Paired-end sequencing is not required to get the best results."

The Ion PGM sequencing 400 kit is ideal for applications that require capturing all the genetic variation in a long exon on a single read. For instance, long reads are critical for researchers trying to interpret genetic data from human leukocyte antigen (HLA) genes or 16S ribosomal genes.

"Sequencing the V1-V2 region of the bacterial 16s rRNA gene would not be possible on the Ion PGM without the longer 400 base pair reads," said Dr. George Watts, Research Assistant Professor and Co-Director, Genomic Shared Service, University of Arizona Cancer Center. "Using 400 base pair reads allows us to increase the information density of the amplicons and better define the constituents of complex microbial populations."

Ion Torrent continues to see rapid increases in accuracy on its Ion PGM and Ion Proton Sequencers as a result of consistent improvements in its algorithms. The new Torrent Suite v3.4 incorporates algorithmic improvements in both raw accuracy and consensus variant calling. These improvements enable both the Ion PGM and Ion Proton semiconductor sequencing platforms to routinely achieve greater than 99.996 percent consensus accuracy.

Life Technologies is also introducing two additional products, capping a year of extraordinary innovation that made the Ion PGM Sequencer the fastest-selling sequencer in the world:

  • The Ion Total RNA-Seq Kit for AB Library Builder, which is designed to make cDNA library preparation for the semiconductor sequencing simple, fast and flexible. The Ion Total RNA-Seq Library Kit for AB Library Builder System enables the construction of cDNA libraries from both whole transcriptome and purified small RNA (miRNA) populations, allowing researchers to analyze all types of RNA molecules.
  • The Thermo Scientific® MuSeek Library Preparation Kit, provides a fast and simple transposon-based method for preparing high-quality genomic DNA libraries for the Ion PGM Sequencer. The kit utilizes MuA transposase enzyme for fragmentation and simultaneous tagging of the target DNA, eliminating the need for separate shearing and adaptor ligation steps. Life Technologies is excited to offer this new kit, which enables library construction in as little as 90 minutes, resulting in significant savings in time and cost.

The Ion Torrent products discussed in this press release are for Research Use Only, not for use in diagnostic procedures.

About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum, with more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent, Applied Biosystems®, Invitrogen, Gibco®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website: http://www.lifetechnologies.com.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Media Contacts:
Wes Conard
Life Technologies Corporation
wes.conard@lifetech.com
415-385-4455

SOURCE Life Technologies



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->